JP2022141773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022141773A5 JP2022141773A5 JP2022111844A JP2022111844A JP2022141773A5 JP 2022141773 A5 JP2022141773 A5 JP 2022141773A5 JP 2022111844 A JP2022111844 A JP 2022111844A JP 2022111844 A JP2022111844 A JP 2022111844A JP 2022141773 A5 JP2022141773 A5 JP 2022141773A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbocyclyl
- pharmaceutically acceptable
- compound
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004452 carbocyclyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 230000001037 epileptic effect Effects 0.000 claims 2
- 201000007547 Dravet syndrome Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024084718A JP7801794B2 (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
| JP2025279047A JP2026062794A (ja) | 2016-11-28 | 2025-12-23 | 化合物及びその使用方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427044P | 2016-11-28 | 2016-11-28 | |
| US62/427,044 | 2016-11-28 | ||
| US201762458306P | 2017-02-13 | 2017-02-13 | |
| US62/458,306 | 2017-02-13 | ||
| US201762552073P | 2017-08-30 | 2017-08-30 | |
| US62/552,073 | 2017-08-30 | ||
| JP2019548536A JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
| PCT/US2017/063533 WO2018098499A1 (en) | 2016-11-28 | 2017-11-28 | Compounds and their methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548536A Division JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024084718A Division JP7801794B2 (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022141773A JP2022141773A (ja) | 2022-09-29 |
| JP2022141773A5 true JP2022141773A5 (https=) | 2023-06-20 |
| JP7495962B2 JP7495962B2 (ja) | 2024-06-05 |
Family
ID=62195384
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548536A Active JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
| JP2022111844A Active JP7495962B2 (ja) | 2016-11-28 | 2022-07-12 | 化合物及びその使用方法 |
| JP2024084718A Active JP7801794B2 (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
| JP2025279047A Pending JP2026062794A (ja) | 2016-11-28 | 2025-12-23 | 化合物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548536A Active JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024084718A Active JP7801794B2 (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
| JP2025279047A Pending JP2026062794A (ja) | 2016-11-28 | 2025-12-23 | 化合物及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11629146B2 (https=) |
| EP (2) | EP4397308A3 (https=) |
| JP (4) | JP7105797B2 (https=) |
| CN (2) | CN110337295B (https=) |
| AU (3) | AU2017364901A1 (https=) |
| BR (1) | BR112019010880A2 (https=) |
| CA (2) | CA3281817A1 (https=) |
| DK (1) | DK3548033T3 (https=) |
| ES (1) | ES2992063T3 (https=) |
| FI (1) | FI3548033T3 (https=) |
| HU (1) | HUE068842T2 (https=) |
| PL (1) | PL3548033T3 (https=) |
| PT (1) | PT3548033T (https=) |
| WO (1) | WO2018098499A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019232209A1 (en) * | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| BR112021003224A2 (pt) | 2018-08-20 | 2021-07-20 | Rogcon, Inc. | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| WO2021039961A1 (ja) * | 2019-08-30 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体 |
| EP4065124A4 (en) * | 2019-11-26 | 2023-12-06 | Praxis Precision Medicines, Inc. | ION CHANNEL MODULATORS |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US12552797B2 (en) * | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| AU2022343895A1 (en) * | 2021-09-13 | 2024-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Cyclopropyl-(hetero)aryl-substituted ethylsulphonylpyridine derivatives |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| EP4598927A2 (en) * | 2022-10-07 | 2025-08-13 | Tenvie Therapeutics Inc. | Compounds, compositions, and methods |
| CN119613413B (zh) * | 2024-12-26 | 2026-02-06 | 上海皓元医药股份有限公司 | 一种非唑奈坦的制备方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| CA1080712A (en) * | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
| US4112095A (en) * | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9507348D0 (en) | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| MXPA05012850A (es) * | 2003-05-29 | 2006-05-17 | New River Pharmaceuticals Inc | Compuestos de anfetamina resistentes al abuso. |
| AU2005212096B2 (en) | 2004-02-18 | 2010-12-16 | Msd K.K. | Nitrogenous fused heteroaromatic ring derivative |
| WO2006061428A2 (en) * | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| US20100088778A1 (en) | 2005-06-16 | 2010-04-08 | John Charles Mulley | Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100125091A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| JP5657566B2 (ja) | 2008-12-24 | 2015-01-21 | バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． | 医薬品 |
| JP5340798B2 (ja) | 2009-05-07 | 2013-11-13 | タイガースポリマー株式会社 | 地中埋設管の製造方法 |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| US8952034B2 (en) * | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| US9139576B2 (en) | 2011-05-03 | 2015-09-22 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| CA2849505A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| US9586963B2 (en) | 2011-09-27 | 2017-03-07 | Genfit | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists |
| CN103122000B (zh) | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| US20140329755A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| AU2014364783B2 (en) | 2013-12-19 | 2017-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| EP3152213B1 (en) * | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| ES2912073T3 (es) | 2014-06-20 | 2022-05-24 | Mitsubishi Chem Corp | Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| KR101819433B1 (ko) | 2014-06-26 | 2018-01-16 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체 |
| JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| US20210188839A1 (en) | 2016-11-28 | 2021-06-24 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| EP4065124A4 (en) | 2019-11-26 | 2023-12-06 | Praxis Precision Medicines, Inc. | ION CHANNEL MODULATORS |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
-
2017
- 2017-11-28 DK DK17874657.4T patent/DK3548033T3/da active
- 2017-11-28 EP EP24160394.3A patent/EP4397308A3/en active Pending
- 2017-11-28 FI FIEP17874657.4T patent/FI3548033T3/fi active
- 2017-11-28 US US16/464,468 patent/US11629146B2/en active Active
- 2017-11-28 CA CA3281817A patent/CA3281817A1/en active Pending
- 2017-11-28 PT PT178746574T patent/PT3548033T/pt unknown
- 2017-11-28 CN CN201780084790.8A patent/CN110337295B/zh active Active
- 2017-11-28 EP EP17874657.4A patent/EP3548033B1/en active Active
- 2017-11-28 CN CN202310582446.9A patent/CN116763791A/zh active Pending
- 2017-11-28 HU HUE17874657A patent/HUE068842T2/hu unknown
- 2017-11-28 PL PL17874657.4T patent/PL3548033T3/pl unknown
- 2017-11-28 WO PCT/US2017/063533 patent/WO2018098499A1/en not_active Ceased
- 2017-11-28 BR BR112019010880-7A patent/BR112019010880A2/pt not_active Application Discontinuation
- 2017-11-28 CA CA3045121A patent/CA3045121C/en active Active
- 2017-11-28 ES ES17874657T patent/ES2992063T3/es active Active
- 2017-11-28 AU AU2017364901A patent/AU2017364901A1/en not_active Abandoned
- 2017-11-28 JP JP2019548536A patent/JP7105797B2/ja active Active
-
2022
- 2022-07-12 JP JP2022111844A patent/JP7495962B2/ja active Active
-
2023
- 2023-03-10 US US18/119,963 patent/US20230322790A1/en not_active Abandoned
- 2023-12-14 AU AU2023282271A patent/AU2023282271A1/en not_active Abandoned
-
2024
- 2024-05-24 JP JP2024084718A patent/JP7801794B2/ja active Active
- 2024-12-06 US US18/971,281 patent/US20250163068A1/en active Pending
-
2025
- 2025-09-23 AU AU2025237912A patent/AU2025237912A1/en active Pending
- 2025-12-23 JP JP2025279047A patent/JP2026062794A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022141773A5 (https=) | ||
| JP2024100974A5 (https=) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2017524025A5 (https=) | ||
| JP2009536620A5 (https=) | ||
| RU2004126671A (ru) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 | |
| JP2020502047A5 (https=) | ||
| JP2011500758A5 (https=) | ||
| JP2013532652A5 (https=) | ||
| JP2018533593A5 (https=) | ||
| JP2010518128A5 (https=) | ||
| JP2005523922A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| JP2018511647A5 (https=) | ||
| JP2009524691A5 (https=) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2005539045A5 (https=) | ||
| JP2011513410A5 (https=) | ||
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| JP2019527724A5 (https=) | ||
| JP2020128426A5 (https=) | ||
| JP2018529690A5 (https=) | ||
| JP2018525430A5 (https=) | ||
| JP2021534227A5 (https=) | ||
| JPWO2019213445A5 (https=) |